Additionally, several studies have demonstrated that patients with renal cell carcinoma with Xp11.2 translocation with metastases that have been treated with Cabozantinib, a c-Met and VEGFR2 tyrosine kinase inhibitor, had better and more durable outcomes compared to those treated with other VEGF inhibitors or other tyrosine kinase inhibitors [56,57]. The gene discussed is MET; the disease is renal cell carcinoma.